Fierce Pharma10h
Merck lays out subcutaneous Keytruda data in lung cancer amid patent brawl with Halozyme
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
Fierce Biotech11h
Candel’s lung cancer survival data light path toward pivotal trial in subpopulation
Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...
BioSpace13h
J&J’s Lung Cancer Combo Bests AstraZeneca’s Tagrisso, Reducing Risk of Death 25%
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients
Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...
CURE2d
Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer
Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.
Multimodal multitask foundation model enhances lung cancer screening and beyond
Lung cancer is one of the most challenging diseases, making early diagnosis crucial for effective treatment. Fortunately, ...
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial ...
Increased use of chest X-rays linked to earlier lung cancer diagnosis and improved survival
A groundbreaking study has revealed a significant link between the frequency of chest X-ray referrals from GPs and earlier ...